Horizon Provides Assurances That Tepezza Sales Are Set To Soar
Guidance Maintained For 30% Growth In 2022
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
You may also be interested in...
TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
Horizon Will Submit Krystexxa sBLA To Strengthen Clinical Profile In Gout
A clinical trial confimred Krystexxa in combination with methotrexate increased response rates in patients with uncontrolled gout.
Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.